41384-83-2

Basic information

• Product Name: 4-NITRO-1-PHENYLIMIDAZOLE
• Synonyms: 4-NITRO-1-PHENYLIMIDAZOLE;4-nitro-1-phenyl-1H-iMidazole
• CAS NO: 41384-83-2
• Molecular Formula: C₉H₇N₃O₂
• Molecular Weight: 189.17078
• Mol File: 41384-83-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 374.6°C at 760 mmHg
• Flash Point: 180.4°C
• Appearance: /
• Density: 1.33g/cm³
• Vapor Pressure: 1.78E-05mmHg at 25°C
• Refractive Index: 1.65
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-NITRO-1-PHENYLIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-NITRO-1-PHENYLIMIDAZOLE(41384-83-2)
• EPA Substance Registry System: 4-NITRO-1-PHENYLIMIDAZOLE(41384-83-2)

Safety Data

• Hazardous Substances Data: 41384-83-2(Hazardous Substances Data)

Usage

General Description

4-Nitro-1-phenylimidazole is a chemical compound with the molecular formula C9H7N3O2. It is a nitro derivative of phenylimidazole, and its structure consists of a nitro group and a phenyl group attached to an imidazole ring. 4-NITRO-1-PHENYLIMIDAZOLE is mainly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. It is also used in the production of dyes, pigments, and other chemical products. 4-Nitro-1-phenylimidazole is known to be toxic and may cause irritation to the skin, eyes, and respiratory system upon exposure. Its potential environmental impact is not well documented, but it is considered to be harmful to aquatic organisms.

InChI:InChI=1/C9H7N3O2/c13-12(14)9-6-11(7-10-9)8-4-2-1-3-5-8/h1-7H

Upstream product

• 62-53-3 aniline 
• 3034-38-6 1H-4⁽⁵⁾-nitroimidazole 
• 6293-66-9 diphenyliodonium p-toluenesulfonate 
• 71100-56-6 1-(p-toluenesulfonyl)-4-nitroimidazole 
• 19182-81-1 1,4-dinitro-1H-imidazole 
• 591-50-4 iodobenzene 

Downstream Products

• 152483-39-1 5-amino-4-nitro-1-phenylimidazole 
• 268538-46-1 phenyl (1-phenyl-1H-imidazol-4-yl)carbamate 
• 1821666-85-6 1-phenyl-1H-imidazole-4-amine hydrochloride 
• 90946-05-7 N-(1-phenyl-1H-imidazol-4-yl)-formamide 
• 83325-36-4 N-(1-phenyl-1H-imidazol-4-yl)-acetamide 
• 318513-66-5 3-phenyl-5-imidazolidinone 
• 103-01-5 N-Phenylglycine 
• 178695-68-6 1-phenyl-4-oximinoimidazolidine 
• 87243-12-7 4⁽⁵⁾-Nitro-5⁽⁴⁾-phenylaminoimidazole 
• 158688-63-2 1-phenyl-1H-imidazol-4-amine 
• 95862-41-2 (3-methyl-5-nitro-3H-imidazol-4-yl)-phenyl-amine 

Relevant articles and documents

WDR5-MYC INHIBITORS

Substituted N-heteroaryl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject such as cancer cell proliferation.

Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design

The frequent deregulation of MYC and its elevated expression via multiple mechanisms drives cells to a tumorigenic state. Indeed, MYC is overexpressed in up to ?50% of human cancers and is considered a highly validated anticancer target. Recently, we discovered that WD repeat-containing protein 5 (WDR5) binds to MYC and is a critical cofactor required for the recruitment of MYC to its target genes and reported the first small molecule inhibitors of the WDR5-MYC interaction using structure-based design. These compounds display high binding affinity, but have poor physicochemical properties and are hence not suitable for in vivo studies. Herein, we conducted an NMR-based fragment screening to identify additional chemical matter and, using a structure-based approach, we merged a fragment hit with the previously reported sulfonamide series. Compounds in this series can disrupt the WDR5-MYC interaction in cells, and as a consequence, we observed a reduction of MYC localization to chromatin.

Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors

Src family kinases (SFKs) are a family of non-receptor tyrosine kinases (TKs) implicated in the regulation of many cellular processes. The aberrant activity of these TKs has been associated with the growth and progression of cancer. In particular, c-Src i